Business
Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting
Oral presentation on BRACELET-1 to take place on June 3, 2023 SAN DIEGO and CALGARY, AB, April 26, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oral presentation on BRACELET-1 to take place on June 3, 2023\nSAN DIEGO and CALGARY, AB, April 26, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from June 2 – 6, 2023 in Chicago, Illinois and online.\n\"Being selected for an oral presentation at ASCO is an immense honor that speaks to the importance of BRACELET-1's results to key opinion leaders and other critical stakeholders in breast cancer,\" said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. \"ASCO is widely recognized as one of the world's premier oncology conferences, and we're thrilled that our collaborators at PrECOG will have such a prestigious venue to present the randomized phase 2 BRACELET-1 trial.\"\nDetails on the abstract and corresponding presentation are shown below.\nTitle: BRACELET-1 (PrE0113): Inducing an Inflammatory Phenotype in Metastatic HR+/HER2- Breast Cancer with the Oncolytic Reovirus Pelareorep in Combination with Paclitaxel and Avelumab\nPresentation Type: Oral\nAbstract Number: 1012\nSession Type: Clinical Science Symposium\nSession Title: The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Harnessing the Breast Cancer Immune Response\nSession Date and Time: June 3, 2023 | 1:15 p.m. – 2:45 p.m. CT\nThe abstract will be published on the ASCO Annual Meeting website at 5:00 p.m. ET on May 25, 2023.\nAbout BRACELET-1\nAdditional information on the BRACELET-1 study can be found at https://clinicaltrials.gov/ct2/home and the identifier (NCT number) NCT04215146.\nAbout Oncolytics Biotech Inc.\nOncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning \"cold\" tumors \"hot\" -- through innate and adaptive immune responses to treat a variety of cancers.\nPelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitor...